Role of chemokine receptor CXCR7 in bladder cancer progression

Hao, Mingang; Zheng, Jianghua; Hou, Kailin; Wang, Jinglong; Chen, Xiaosong; Lu, Xiaojiong; Jun-jie, BO; Xu, Chen; Shen, Kunwei; Wang, Jianhua

doi:10.1016/j.bcp.2012.04.007

Cited by 75 publications

(70 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Here, everolimus alone or combination with tamoxifen treatment can inhibit mTOR activity, but pAkt expression was upregulated in ER-positive breast cancer cell lines and in vivo tumor model, which may explain the relative low response rate in metastatic breast cancer therapy (11). Theoretically, inhibition of the alterations in PI3K/Akt/mTOR pathway nodal points may reduce the feedback pAkt activation and restore treatment sensitivity (18). He and colleagues reported that resveratrol, a natural phytoalexin, enhanced the antitumor activity of rapamycin in multiple breast cancer cell lines mainly by suppressing rapamycin-induced Akt signaling (20).…”

Section: Discussionmentioning

confidence: 99%

“…Cells were then treated with single or combination agents for 10 minutes, 30 minutes, 60 minutes, 24 hours, and 48 hours. Procedures for protein extraction and analysis were described previously (18).…”

Section: Western Blot Analysesmentioning

confidence: 99%

“…The slides were examined, and the sprouts were counted from 5 random fields using a microscope (Â200). Further methods for endothelial sprout formation assay analysis were described in our previous report (18).…”

Section: Endothelial Sprout Formation Assaymentioning

confidence: 99%

See 2 more Smart Citations

Dual Inhibition of PI3K and mTOR Mitigates Compensatory AKT Activation and Improves Tamoxifen Response in Breast Cancer

Chen

Zhao

Hao

et al. 2013

Molecular Cancer Research

Self Cite

View full text Add to dashboard Cite

Everolimus, an mTOR inhibitor, showed great clinical efficacy in combination with tamoxifen, letrozole, or exemestane for the treatment of estrogen receptor-positive (ER+) breast cancer. However, its antitumor activity was shown to be compromised by a compensatory process involving AKT activation. Here, it was determined whether combining an additional PI3K inhibitor can reverse this phenomenon and improve treatment efficacy. In breast cancer cells

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Western Blot Analysesmentioning

confidence: 99%

See 1 more Smart Citation

Dual Inhibition of PI3K and mTOR Mitigates Compensatory AKT Activation and Improves Tamoxifen Response in Breast Cancer

Chen

Zhao

Hao

et al. 2013

Molecular Cancer Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…In cervical cancer research [30], colorectal cancer research by Xu et al [19] cutaneous squamous cell carcinoma research by Hu et al [21] renal cancer research by Wang et al [26] and gallbladder cancer research by Yao et al [27] all of these studies have consistent results for tumor grade, stage and lymph node metastasis [30][31][32][33][34]. These significant clinicopathological relative factors revealed their roles in tumor development [35][36][37][38][39][40]. This meta-analysis has drawn the distance between CXCR7 and the clinicopathological indicators closer.…”

Section: Discussionmentioning

confidence: 99%

Meta-analysis of CXCR7 Expression Related to Clinical Prognosis in Cancers

Qing¹,

Wen²

2016

J Integr Oncol

View full text Add to dashboard Cite

Purpose: Recently, higher expression of chemokine receptors in patients with various cancer types has been observed and indicated to have prognostic significance in the clinical progression of cancers. Former research has determined that CXCR7, as a member of chemokine receptor C-X-C family, empowers greater affinity with chemokine CXCL12 than CXCR4. The present study investigated the correlation of clinical characteristics and CXCR7 expression in cancers using meta-analysis. Methods:A comprehensive search on Pubmed and Web of Science identified CXCR7-related clinical studies. Methodological quality of these studies was evaluated and all the data were extracted, calculated and analyzed. This meta-analysis was carried out with Stata 12.0. Results:Fifteen eligible studies consisting of 1780 participants were included. The results showed that CXCR7 significantly relates to tumor occurrence (pooled RR=3.12, 95% CI: 1.71-5.70, P=0.000), tumor grades (pooled RR=1.41, 95% CI: 1.14-1.75, P=0.002), tumor stages (pooled RR=1.51, 95% CI: 1.26-1.82, P=0.000) and lymph node metastasis (pooled RR=1.49, 95% CI: 1.14-1.94, P=0.000), respectively. Conclusion:Highly expressed chemokine receptor CXCR7 potentially increases tumor occurrence risk. Higher CXCR7 expression is associated with poorer prognosis, advanced stages, differentiation grades and poor lymph node metastasis in patients with various cancers. Thus, highly expressed CXCR7 could be a potential biomarker in the prognosis of cancers.

show abstract

“…Univariate and multivariate analyses for bladder transitional cell carcinoma lymph node metastasis. which is expressed in several human cell lines and vascular endothelial cells (19). The expression of CCR7 on tumor cells has mainly been reported for breast, non-small cell lung, prostate, head and neck, stomach and colorectal cancer, in addition to melanoma, chronic lymphocytic and T cell leukemia and non-Hodgkin's lymphoma (20).…”

Section: Discussionmentioning

confidence: 99%

CCR7 as a predictive biomarker associated with computed tomography for the diagnosis of lymph node metastasis in bladder carcinoma

Chen

Liu

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

Abstract. The aim of the present study was to investigate whether the expression levels of CC-chemokine receptor 7 (CCR7) combined with computed tomography (CT) was associated with lymph node metastasis in bladder transitional cell carcinoma (BTCC). For this purpose, 115 cases of BTCC were analyzed at the Department of Urology of Xiangya Hospital, Central South University (Changsha, China). Preoperative CT scans of abdomen and pelvis, immunohistochemistry of CCR7 expression in the tumor specimens and pathological findings for lymph node metastasis were assessed. In addition, the sensitivity, specificity and accuracy of CCR7 and CT for the diagnosis of lymph node metastasis in BTCC were evaluated separately and jointly. The expression levels of CCR7 were observed to be significantly higher in BTCC than in normal controls (P<0.01). Multivariate analysis indicated that the overexpression of CCR7 was an independent predictor for lymph node metastasis in BTCC (P<0.05). The sensitivity, specificity and accuracy of CCR7 combined with CT scan for the diagnosis of lymph node metastasis in BTCC were 92.3, 83.6 and 70.0%, respectively. By contrast, the sensitivity, specificity and accuracy of CCR7 alone were 88.1, 69.9 and 76.5%, respectively, while the sensitivity, specificity and accuracy of CT alone were 52.4, 79.5 and 69.6%, respectively. The results of the present study indicated that CCR7 is an independent predictor of lymph node metastasis in BTCC. Therefore, the use of CCR7 combined with CT may improve the accuracy of the diagnosis of lymph node metastasis in BTCC.

show abstract

Role of chemokine receptor CXCR7 in bladder cancer progression

Cited by 75 publications

References 42 publications

Dual Inhibition of PI3K and mTOR Mitigates Compensatory AKT Activation and Improves Tamoxifen Response in Breast Cancer

Dual Inhibition of PI3K and mTOR Mitigates Compensatory AKT Activation and Improves Tamoxifen Response in Breast Cancer

Meta-analysis of CXCR7 Expression Related to Clinical Prognosis in Cancers

CCR7 as a predictive biomarker associated with computed tomography for the diagnosis of lymph node metastasis in bladder carcinoma

Contact Info

Product

Resources

About